Lexicon Pharmaceuticals (NASDAQ:LXRX) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported $2.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.31 by $0.80, Fidelity Earnings reports. The business had revenue of $294.45 million for the quarter, compared to the consensus estimate of $12.00 million. Lexicon Pharmaceuticals’s quarterly revenue was up 4124.5% on a year-over-year basis. During the same period in the prior year, the business posted ($0.26) EPS.
NASDAQ:LXRX traded down $0.36 during trading hours on Friday, hitting $3.52. 1,316,800 shares of the company’s stock traded hands, compared to its average volume of 1,292,482. Lexicon Pharmaceuticals has a 52 week low of $1.13 and a 52 week high of $9.15. The firm has a market cap of $419.77 million, a P/E ratio of -3.09 and a beta of 0.95. The business’s fifty day simple moving average is $3.52 and its two-hundred day simple moving average is $4.21.
Several equities research analysts recently issued reports on LXRX shares. Citigroup lowered Lexicon Pharmaceuticals from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $3.00 to $4.00 in a research note on Friday. Stifel Nicolaus lowered Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their price objective for the company from $10.00 to $4.00 in a research note on Monday, July 29th. G.Research raised Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Gabelli raised Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a research note on Wednesday, September 11th. Finally, BidaskClub lowered Lexicon Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. Lexicon Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $6.45.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.